title: Polycystic ovary syndrome and chronic inflammation: pharmacotherapeutic implications.
abstract: OBJECTIVE
  To examine the relationship between polycystic ovary syndrome (PCOS), cardiovascular risk factors, cardiovascular disease (CVD), and chronic inflammation and analyze data regarding pharmacologic therapies that are recommended to reduce CVD risk in PCOS and the impact of those therapies on chronic inflammation.
  
  
  METHODS
  A search of MEDLINE (1950-October 2011) was conducted to identify clinical studies pertaining to the identification and treatment of CVD and chronic low-grade inflammation in PCOS. Search terms included polycystic ovary syndrome, cardiovascular disease, inflammation, metformin, thiazolidinedione, and statin. Bibliographies of these studies and review articles were also examined.
  
  
  METHODS
  English-language clinical studies evaluating the effect of metformin, thiazolidinediones, and statins on inflammatory markers, endothelial function, adhesion molecules, fibrinolysis, cytokines, and adipokines in PCOS were included.
  
  
  RESULTS
  Women with PCOS have an increased prevalence of many cardiovascular risk factors including obesity, android fat distribution, insulin resistance, impaired glucose tolerance, diabetes, dyslipidemia, hypertension, and metabolic syndrome. Markers of chronic low-grade inflammation, which are associated with an increased risk of CVD, are also elevated in PCOS. Clinical guidelines recommend the use of insulin sensitizers and statins to prevent CVD in some patients with PCOS. Current literature indicates that each of these medication classes has beneficial effects on inflammation, as well. Although there are currently no studies to determine whether these treatments decrease CVD in PCOS, it can be hypothesized that drugs impacting chronic inflammation may reduce cardiovascular risk. Some studies show that metformin, thiazolidinediones, and statins have beneficial effects on inflammatory markers in PCOS; however, the data are inconsistent.
  
  
  CONCLUSIONS
  There is insufficient information to recommend any pharmacologic therapies for their antiinflammatory effects in PCOS in the absence of other indications such as diabetes and dyslipidemia.
authors.affiliation: Department of Clinical and Administrative Sciences, College of Pharmacy, University of Louisiana at Monroe, USA. sirmans@ulm.edu
authors.forename: Susan Maureen
authors.initials: SM
authors.lastname: Sirmans
authors.forename: Emily
authors.initials: E
authors.lastname: Weidman-Evans
authors.forename: Victoria
authors.initials: V
authors.lastname: Everton
authors.forename: Daniel
authors.initials: D
authors.lastname: Thompson
mesh_terms: D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000378:metabolism / Q000517:prevention & control*; D002908:Chronic Disease; D005260:Female; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism; D012307:Risk Factors